The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- IPF Patient Meeting Highlights Severe Unmet Need; Patients Have Difficulty Expressing “Ideal Therapy;” Focus on Oxygen Sep. 29, 2014
- Rapid Diagnostic Development In Antimicrobials Getting Boost From Drug Sponsors, Progress Appears Slow—NIAID Workshop Sep. 29, 2014
- BARDA Role in Anti-Infective Development Broadened By Obama Exec Order; Incentive Fund Will Need Legislation Sep. 24, 2014
See More Research Notes